WEGOVY 0.25MG INJECTION – Semaglutide 0.25mg

WEGOVY 0.25MG INJECTION contains Semaglutide 0.25mg, a GLP-1 receptor agonist specifically used for chronic weight management in eligible patients with obesity or overweight accompanied by a weight-related health condition. It is used together with a reduced-calorie diet and increased physical activity.

Semaglutide mimics the activity of the naturally occurring hormone GLP-1. It acts on GLP-1 receptors involved in appetite and energy regulation, helping reduce food intake and supporting weight reduction when combined with appropriate lifestyle measures.

Product Information

Weight Management

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:

• BMI ≥30 kg/m² (obesity), or
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity.

The Indian prescribing information also includes an indication for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

How Semaglutide Works

Semaglutide activates GLP-1 receptors, which can:

• Reduce appetite
• Reduce food intake
• Increase feelings of fullness
• Influence energy intake and body weight

Wegovy should be used together with appropriate dietary and physical-activity measures.

Dosage & Dose Escalation

WEGOVY 0.25MG is the starting dose.

The standard escalation schedule is:

Dose escalation is used to reduce the likelihood of gastrointestinal adverse effects. If significant gastrointestinal symptoms occur, dose escalation may be delayed or the previous dose may be resumed until symptoms improve. Weekly doses above 2.4mg are not recommended.

How to Use

• Inject once weekly.
• Administer subcutaneously in the abdomen, thigh, or upper arm.
• The injection can be taken at any time of day, with or without meals.
• Use the injection on the same day each week.
• Rotate injection sites when appropriate.
• Do not inject intravenously or intramuscularly.